XNK Therapeutics AB (“XNK” or the “Company”), a Swedish clinical stage immunotherapy company treating cancer by developing novel NK cell-based therapies, today announced the completion of a private placement of SEK 64 million. The purpose of the issue is primarily to finance the Company’s research and development efforts.
“XNK has made significant progress with its technology platform and this new funding will be key to continue the clinical development of our leading investigational drug candidate,” said Johan Liwing, CEO of XNK.
For more information, please contact:
Johan Liwing, CEO, XNK Therapeutics
Tel: +46 706 70 36 75
E-mail: johan.liwing@xnktherapeutics.com
About XNK Therapeutics AB
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company’s platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow’s cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit xnktherapeutics.com.
